#EULAR2022
How to treat (HOT)
Difficult to treat RA
Definition:
#EULAR2022
How to treat (HOT)
Difficult to treat RA
🟣 FMS is asso with more severe RA
🟣 Pts with D2T RA have higher comorbidity burden
🟣 Obesity is also a mediator of non Response
#EULAR2022
How to treat (HOT)
Difficult to treat RA
This was interesting
🟢 Pts with D2T RA may have a pausi immune phenotype
🟢 This might explain poor response to Rx
#EULAR2022
Pts with D2T RA have
🟣 ⬆️Comorbidities, DMRD ADRs, FMS, Depression, Anxiety
🟣⬇️ QOL
🟣 3 phenotypes have been found
🟪 Rx Non-Adherent
🟪 Obese with Pain syndrome
🟪 True Refractory
#EULAR2022
How to treat (HOT)
Difficult to treat RA
🟣 Adverse events contribute max to treatment non-adherence
🟣Relation with HC provider the most Imp facilitator
🟣D2T RA has higher economic burden then nonD2T RA
#EULAR2022
How to treat (HOT)
Difficult to treat RA
Points to consider for Managing D2T RA
#EULAR2022
How to treat (HOT)
Difficult to treat RA
Overarching principles and Research agenda
#EULAR2022
How to treat (HOT)
Difficult to treat RA
Summary slides
Awesome talk 👌🏻🤩
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#EULAR2022
Pain in rheumatic and musculoskeletal diseases
😩Pathophysiology of pain in patients with RMDs is not always Nociceptive and can be nociplastic
😩Differentiation between inflammation-related and unrelated pain is important
#EULAR2022
Pain in rheumatic and musculoskeletal diseases
😩Pain can be Nociceptive, Neuropathic and Nociplastic
😩Or can be primary/Secondary
😩Pain sensitisation, processing and response are important for proper assimilation of pain
#EULAR2022
😩No standard method to measure central pain
😩FMS can be present in upto 50% of patients
😩Asso with Higher disease activity and higher biologic use/change
😩A no. of central mechanisms contribute to pain
#EULAR2022
What is New (WIN)
Osteoarthritis – evolving treatments
This talk is a must-watch on-demand - highly recommended
🗝Proposed NICE-UK guidelines for
#EULAR2022
🗝Most trials have tried correcting catabolic pathway
🗝 Most trials in OA have failed
🗝Cartilage though sparsely cellular/vascular exquisitely sensitive to injury
🗝 Max polymorphism in OA is found in the Anabolic pathway
#EULAR2022
What is New (WIN)
Osteoarthritis – evolving treatments
🗝Shear stress leads to damage while compression leads to regeneration
🗝Has been utilized in Joint distraction showing good results
#EULAR2022
Rheumatology across boundaries
The eye in rheumatic diseases
🧿The Pathophysiology of Uveitis is poorly understood
🧿 Uveitis is thought to be due to enthesitis of ciliary body attachment
🧿TH17 and TH1 are major mediators of inflammation
#EULAR2022
Rheumatology across boundaries
The eye in rheumatic diseases
🧿 Most common extra-articular feature
🧿 HLA-B27+vity, Recurrent uveitis and IBP 🚩 for rheumatology referral
#EULAR2022
Rheumatology across boundaries
The eye in rheumatic diseases
🧿 Non-Anterior non infectious Uveitis has a no of causes 👉🏻 makes studying the disease difficult
🧿 Sarcoid, Behcet's other imp causes
🧿 Topical Rx 1st for Anterior Uveitis
🧿 Systemic 1st for NIU
#EULAR2022
How To Treat (HOT)
Anti-phospholipid syndrome
#EULAR2022
How To Treat (HOT)
Anti-phospholipid syndrome
🩸Primary Thromboprophylaxis
🩸Aspirin is recommended but might not be sufficient
🩸VKA use is asso. ⬆️ Bleeding risk (Risk>Benefit)
#EULAR2022
How To Treat (HOT)
Anti-phospholipid syndrome
🩸Secondary Prophylaxis
🩸INR: 2-3 for venous thrombosis (Controversial)
🩸Is not effective in preventing arterial events though
#EULAR2022
IBD management for Rheumatologist
🔎The options have been increasing over the years
🔎Remission rates have still not crossed 30-40% Ballpark
#EULAR2022
IBD management for Rheumatologist
🔎Target of therapy is
♦️Clinical remission in short term
♦️Histological remission in medium-term
♦️Disease Modification in Long
🔎Histological activity better marker of future Flare
#EULAR2022
IBD management for Rheumatologist
🔎Very Few Head to head trial to decide biologic of choice
🔎 Vedoli>Adali but Ustki=Adali
#EULAR2022
New treatment strategies and approaches to young adults with inflammatory myositis
Treatment options available their doses in IIM
#EULAR2022
New treatment strategies and approaches to young adults with inflammatory myositis
♦️MTX+GC>>MTX+CIC>GC alone
#EULAR2022
New treatment strategies and approaches to young adults with inflammatory myositis
🪩RIM trial
♦️Better response in JDM
♦️Antibody positive (Mi2,Jo1 +ve ) performed better than Ab negetive